Human Immunology News 6.06 February 13, 2018 | |
| |
TOP STORYU of T Researchers Develop New Generation CAR T-Cells for Cancer Therapy With CAR T-cell therapy one of the promising technologies emerging in targeted cancer treatment, scientists have taken a step forward in improving the potential effectiveness of this therapeutic approach. They outlined a novel method for production of these so-called living drugs. [Press release from the University of Toronto discussing online prepublication in Nature Medicine] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Sorafenib-related IL-15 production caused an increase in CD8+CD107a+IFN-γ+ T cells with features of longevity, which eradicated leukemia in secondary recipients. [Nat Med] Abstract Peanut allergy individuals had tissue and follicle-homing peanut-responsive CD4+ T cells with a heterogeneous pattern of Th2 differentiation, while controls had undetectable T cell responses to peanut. [J Allergy Clin Immunol] Abstract Targeting JAK2 Reduces GvHD and Xenograft Rejection through Regulation of T Cell Differentiation Investigators demonstrated that inhibition of janus kinase 2 (JAK2) significantly decreases graft-versus-host disease (GvHD) and maintains tumor killing by the donor T cells. Pharmacologic blockade of JAK1 and JAK2 in myelofibrosis patients is known to impair human T cell subsets broadly. [Proc Natl Acad Sci USA] Abstract | Press Release miR-125b-5p and miR-99a-5p Downregulate Human γδ T-Cell Activation and Cytotoxicity Scientists profiled the miRNA expression patterns in human peripheral γδ T cells from 21 healthy donors and identified 14 miRNAs that were differentially expressed between peripheral αβ T cells and γδ T cells. [Cell Mol Immunol] Abstract Researchers optimized the non-viral piggyBac transposon system to engineer human T cells for the expression of epidermal growth factor receptor (EGFR)-CAR, consisting of EGFR scFv, transmembrane domain, and intracellular 4-1BB-CD3ζ signaling domains. [Cell Death Dis] Full Article To assess the expression of triggering receptor expressed on myeloid cells (TREM-1) on blood Vδ2 T cells from pulmonary tuberculosis (TB) patients and investigate its mechanism of induction, researchers exploited flow cytometry analysis to study the expression of TREM-1 on Vδ2 T cells from active pulmonary TB patients and control subjects. [J Immunol] Abstract The authors investigated the frequencies, phenotype and function of circulating Tfh-like CD4+CXCR5+ T cells in adults receiving an oral inactivated enterotoxigenic Escherichia coli vaccine. [Sci Rep] Full Article Scientists investigated the immune response of human peripheral blood mononuclear cells to commercially available silicone breast implants in vitro. [PLoS One] Full Article Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSPerpetual Complexity: Predicting Human CD8+ T Cell Responses to Pathogenic Peptides The authors review some of the discoveries that initiated the development of peptide prediction algorithms, and outline some of the current available online tools for CD8+ T cell epitope prediction. [Immunol Cell Biol] Abstract Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
SCIENCE NEWSZiopharm Oncology Presents Data on Very Rapid Production of CAR T Cells Ziopharm Oncology, Inc. announced data demonstrating point-of-care manufacturing of human T cells expressing CAR that persist and have an anti-tumor effect in preclinical models were presented. [Press release from Ziopharm Oncology, Inc. discussing research presented at the Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond, Keystone] Press Release | |
| |
INDUSTRY NEWSPieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration Pieris Pharmaceuticals, Inc. and Seattle Genetics, Inc. announced they have entered into a collaboration and license agreement with the goal of developing multiple targeted bispecific immuno-oncology treatments for solid tumors and blood cancers. [Pieris Pharmaceuticals, Inc.] Press Release Sosei Provides an Update on Its Immuno-Oncology Clinical Program with AstraZeneca Sosei Group Corporation announced that its immuno-oncology collaboration with AstraZeneca is progressing well. The first patient has been dosed in an expansion cohort in the Phase Ib segment of the Phase I study in advanced solid tumors. [Sosei Group Corporation] Press Release Physicians and researchers from the Medical College of Wisconsin, Froedtert Hospital, Children’s Hospital of Wisconsin, and BloodCenter of Wisconsin have successfully used a new immunology treatment, CAR T-cell therapy, to extend the life of a 52-year-old Wisconsin man. [Medical College of Wisconsin] Press Release Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells Cellectis announced the issuance of two U.S. patents – US 9,855,297 and US 9,890,393 – for the invention of certain uses of RNA-guided endonucleases, such as Cas9 or Cpf1, for the genetic engineering of T-cells. [Cellectis] Press Release NantKwest Inc. announced that the first patient has been dosed in a first-in-human, Phase I clinical study in glioblastoma of HER2.taNK, a novel, natural killer cell-based immuno-oncology therapy using CAR technology in patients. [NantKwest Inc.] Press Release | |
| |
EVENTSNEW Gordon Research Conferences: Chemotactic Cytokines Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Scientist Opportunities – Biomedical Research (Cedars-Sinai) Research Technologist – Cell Separation (STEMCELL Technologies Inc.) Senior Director – Immuno-Oncology Research (Alector LLC) Research Scientist – Oncology Research (MedImmune) Postdoctoral Researcher – Cellular and Molecular Immunology (Karolinska Institutet) Postdoctoral Position – Microbiology and Immunology (University of Maryland) Head of Laboratory – Cancer Vaccines/Oncolytic Viruses (Boehringer Ingelheim) Investigator – Immuno-Oncology (Bristol-Myers Squibb) Scientist – Immuno-Oncology (Bristol-Myers Squibb) Postdoctoral Fellow – Immune Surveillance (University of Massachusetts) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|